




# The Brazilian Journal of INFECTIOUS DISEASES

www.elsevier.com/locate/bjid



## Letter to the Editor

# Low prevalence of human immunodeficiency virus and hepatitis C virus co-infection in a medium size city in southern Brazil



Dear Editor,

Approximately 35.3 million of people are infected with the human immunodeficiency virus (HIV) worldwide, and 20–30% of them are also contaminated with the hepatitis C virus (HCV). The introduction of highly active antiretroviral therapy increased the survival time and improved the quality of life of HIV-infected individuals, however hepatic diseases related to chronic HCV infection became the main cause of morbidity and mortality in these patients.<sup>1</sup> The present work aimed to study the prevalence and risk factors for HCV infection in a sample of HIV-infected patients from a medium size urban center in the countryside of South Brazil.

Adult individuals with HIV receiving care in a reference outpatient treatment center for HIV testing and AIDS treatment in Cruz Alta (located in the Northwest region of the state of Rio Grande do Sul, Brazil) were consecutively enrolled in the study from July 2011 to August 2012. Socio-demographic and

potential risk factors for HIV infection were obtained with a standardized individual questionnaire. General laboratory and clinical data were obtained from the medical records. All participants signed an informed consent form. The study was approved by the Research Ethics Committees of the Universidade Luterana do Brasil.

A total of 148 HIV-infected patients were included in the study. Sixteen patients (10.8%) had anti-HCV and HCV-RNA positive results. A total of 13 patients (81.2%) were infected with HCV genotype 1, and three (18.8%) with genotype 3. Use of intravenous drugs and report of possible HIV acquisition by sharing needles were significantly higher in co-infected than in mono-infected patients ( $p < 0.001$ ) (Table 1). The time period since HIV diagnosis was longer in co-infected than in mono-infected patients ( $p = 0.041$ ). A higher proportion of HIV/HCV co-infected patients (100.0%) than mono-infected patients (62.1%) had undergone surgery in the past ( $p = 0.008$ ). In the multivariate analysis, use of injecting drugs ( $p = 0.021$ ), surgery history ( $p < 0.001$ ) and male gender ( $p < 0.001$ ) were

**Table 1 – Distribution of socio-demographic and epidemiological characteristics in HIV-positive patients according to HCV status.**

Variable	Total (n = 148)	HCV-negative (n = 132)	HCV-positive (n = 16)	p
Male gender	67 (45.2)	58 (43.9)	9 (56.3)	0.428
Age (years)	41.9 ± 11.9	41.9 ± 12.2	41.6 ± 8.7	0.898
Education level				0.829
Complete primary education or less	109 (73.6)	97 (73.5)	12 (75.0)	
Secondary or higher education	39 (26.3)	35 (26.5)	4 (25.0)	
Sexual orientation <sup>a</sup>				0.947
Heterosexual	136 (91.8)	120 (90.9)	16 (100.0)	
Homosexual	6 (4.0)	6 (4.5)	–	
Bisexual	5 (3.3)	5 (3.8)	–	
Possible forms of HIV infection <sup>a,b</sup>				
Sex	127 (85.8)	112 (84.8)	15 (93.8)	0.577
Blood transfusion	7 (4.7)	6 (4.5)	1 (6.3)	0.931
Cutting objects	2 (1.3)	2 (1.5)	–	0.878
Sharing needles	5 (3.3)	1 (0.8)	4 (25.0)	<0.001
Time since HIV diagnosis (years) <sup>a</sup>	6.1 ± 5.6	5.7 ± 5.4	8.9 ± 6.1	0.041

**Table 1 – (Continued)**

Variable	Total (n = 148)	HCV-negative (n = 132)	HCV-positive (n = 16)	p
Number of sexual partners in the past 12 months <sup>a</sup>	1.8 ± 2.4	1.8 ± 2.4	2.1 ± 2.2	0.654
Use of condom during last occurrence of sexual intercourse	90 (60.8)	78 (59.1)	12 (75.0)	0.894
Injecting drug use	4 (2.7)	–	4 (25.0)	<0.001
Smoking drug use	22 (14.8)	19 (14.4)	3 (18.8)	0.823
Snorting drug use	24 (16.2)	19 (14.4)	5 (31.3)	0.511
Blood transfusion	38 (25.6)	33 (25.0)	5 (31.3)	0.910
Tattoo	43 (29.0)	35 (26.5)	8 (50.0)	0.120
Piercing	10 (6.7)	7 (5.3)	3 (18.8)	0.123
Surgery	98 (66.2)	82 (62.1)	16 (100.0)	0.008
Endoscopy	34 (22.9)	32 (24.2)	2 (12.5)	0.941
Sharing toothbrushes	19 (12.8)	17 (12.9)	2 (12.5)	0.928
Sharing sharp objects (in salon, manicure, pedicure, barber and personal care)	61 (41.2)	57 (43.2)	4 (25.0)	0.187
Working in the health service	11 (7.4)	9 (6.8)	2 (12.5)	0.686
STD history	46 (31.0)	38 (28.8)	8 (50.0)	0.265
HAART use	111 (75.0)	99 (75.0)	12 (75.0)	0.847

Note: Variables expressed as number (percentage) or mean ± standard deviation.

STD, sex transmitted disease; HAART, highly active antiretroviral therapy.

Bold values are those statistically significant ( $p < 0.05$ ), but this emphasis can be omitted.

<sup>a</sup> Totals do not coincide due to lack of data from certain participants in the study.

<sup>b</sup> Multiple response.

the independent risk factors associated with HIV/HCV co-infection.

The prevalence of HIV/HCV co-infection varies with the geographic region. In Brazil, reports estimated an average of 20.3% of HIV/HCV co-infection, ranging from 3.3% to 82.4% according to the region.<sup>2</sup> Epidemiological studies conducted in the capital cities and metropolitan regions from Brazil have demonstrated high HIV/HCV co-infection, mainly associated to injecting drug use.<sup>2</sup> However, epidemiological reports are sparse from the countryside, limiting a better understanding of these epidemiological aspects in Brazil. The present study focused in the city of Cruz Alta, a medium size urban center with one of the highest incidence rate of HIV/AIDS in Rio Grande do Sul.<sup>3</sup> HIV/HCV co-infection frequency was lower than in the two cities of the metropolitan area of the state, Porto Alegre (31.2%) and Canoas (23.8%).<sup>4,5</sup> Interestingly the frequency of injecting drug users was also lower in the investigated population (2.7%) than those reported in other studies.<sup>4,5</sup> The low HIV/HCV co-infection prevalence is probably related to the low frequency of injecting drug users in the community. This epidemiologic knowledge is essential for the development of specific prevention strategies in small and medium size cities from the Brazilian countryside.

### Conflicts of interest

The authors declare no conflicts of interest.

### Acknowledgments

The authors would like to thank the patients and staff of the Specialized Service (SAE) of Cruz Alta, RS, for their collaboration in the development of this study.

### REFERENCES

- Operskalski EA, Kovacs A. HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies. *Curr HIV/AIDS Rep.* 2011;8:12–22.
- Kuehlkamp VM, Schuelter-Trevisol F. Prevalence of human immunodeficiency virus/hepatitis C virus co-infection in Brazil and associated factors: a review. *Braz J Infect Dis.* 2013;17:455–63.
- Ministério da Saúde (Brasil). Secretaria de Vigilância em Saúde. Departamento de DST, AIDS e Hepatites Virais. *Boletim Epidemiológico – AIDS e DST. Brazil: Ministério da Saúde; ano II, número 1; 2013.*
- Wolff FH, Fuchs SC, Barcellos NN, et al. Co-infection by hepatitis C virus in HIV-infected patients in southern Brazil: genotype distribution and clinical correlates. *PLoS ONE.* 2010;5:e10494.
- Simon D, Michita RT, Béria JU, Tietzmann DC, Stein AT, Lunge VR. Alcohol misuse and illicit drug use are associated with HCV/HIV co-infection. *Epidemiol Infect.* 2014, <http://dx.doi.org/10.1017/S0950268814000041>.

Carina Sperotto Librelotto, Daniel Simon\*, Nilo Ikuta, Vagner Ricardo Lunge

Programa de Pós-Graduação em Biologia Celular e Molecular Aplicada à Saúde, Universidade Luterana do Brasil (ULBRA), Canoas, RS, Brazil

\*Corresponding author at: Programa de Pós-Graduação em Biologia Celular e Molecular Aplicada à Saúde, Universidade Luterana do Brasil, Av. Farroupilha, 8001, Prédio 22, 5° andar, 92425-900 Canoas, RS, Brazil.

E-mail addresses: [daniel.simon@ulbra.br](mailto:daniel.simon@ulbra.br), [danielsimon@uol.com.br](mailto:danielsimon@uol.com.br) (D. Simon).

Received 30 April 2014

Accepted 17 May 2014

Available online 25 July 2014

<http://dx.doi.org/10.1016/j.bjid.2014.05.014>

1413-8670/© 2014 Elsevier Editora Ltda.

Este é um artigo Open Access sob a licença de CC BY-NC-ND